Ocriplasmin

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Conference, Wills Eye Hospital, Biotechnology, Paratriathlon, Medicine, Nightstar, Acquisition, Eli Lilly, Alcon, Retina, ProQR, Drug, MD, Ocriplasmin, Merck & Co., Stargardt disease, Abstract, Protein splicing, Laboratory, Stargardt, Merck, Gene, Genetic, Growth, Biogen, Pharmaceutical industry

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Conference, Wills Eye Hospital, Biotechnology, Paratriathlon, Medicine, Nightstar, Acquisition, Eli Lilly, Alcon, Retina, ProQR, Drug, MD, Ocriplasmin, Merck & Co., Stargardt disease, Abstract, Protein splicing, Laboratory, Stargardt, Merck, Gene, Genetic, Growth, Biogen, Pharmaceutical industry

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019

Retrieved on: 
Lunedì, Settembre 2, 2019
Organ systems, Blindness, Ocriplasmin, Retinopathy, Medicine, Diabetic retinopathy, Diabetes, Ophthalmology, Clinical medicine

Dr Dugel will also be presenting the THR-149 clinical data at the Retina Society 2019 Annual Meeting on 12 September 2019 at The Landmark Hotel in London, UK.

Key Points: 
  • Dr Dugel will also be presenting the THR-149 clinical data at the Retina Society 2019 Annual Meeting on 12 September 2019 at The Landmark Hotel in London, UK.
  • During the EURETINA meeting, Oxurion will also be delivering further podium and poster presentations related to its other advanced clinical candidates, THR-687 and THR-317, as well as Ocriplasmin real world clinical and health economics evidence.
  • EURETINA aims to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists.
  • Other Oxurion presentations at EURETINA:
    A. Wolf presents Ocriplasmin in Clinical Practice: Results from a European Prospective Drug Utilisation Study (TULIP)
    K. Januschowski (on behalf of P. Szurman) presents Effectiveness of ocriplasmin in real-world settings and clinical trials: a systematic literature review
    For further information please contact: